Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + carboplatin + paclitaxel + docetaxel-Swami Rama Himalayan University
- Development stage
- Unknown
- Lead developer
- Swami Rama Himalayan University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to a grouping of platinum-based (cisplatin, carboplatin) and taxane-based (paclitaxel, docetaxel) chemotherapy agents utilized in a clinical study conducted by Swami Rama Himalayan University. These agents are standard-of-care treatments for various solid tumors, including head and neck, breast, and prostate cancers. Cisplatin and carboplatin act as DNA alkylating-like agents that form intra-strand and inter-strand cross-links, inhibiting DNA replication and transcription. Paclitaxel and docetaxel are microtubule stabilizers that bind to the beta-subunit of tubulin, preventing microtubule depolymerization and leading to cell cycle arrest in the G2/M phase. The specific study mentioned evaluates chemotherapy-induced peripheral neuropathy (CIPN) associated with these agents, utilizing biomarkers such as NOX4 expression and vitamin levels to assess severity.
- Brand names
- Taxotere
- Other names
- Cisplatin, Carboplatin, Paclitaxel, Docetaxel
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cisplatin + carboplatin + paclitaxel + docetaxel-Swami Rama Himalayan University.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + carboplatin + paclitaxel + docetaxel-Swami Rama Himalayan University.